The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment of relapsed/refractory multiple myeloma (MM) in 2026?

In this interview, Lonial provides an overview of recent and emerging developments in relapsed/refractory MM, highlighting advances in immune-based therapies and their potential to improve outcomes in the early relapsed setting. He also discusses how these approaches may influence treatment decision-making, the movement of novel therapies into earlier lines of treatment, and the broader implications for future disease management.

Hosted on Acast. See acast.com/privacy for more information.